Reason for Corrigendum:
In the original review, we placed an incorrect citation in the following sentence:
“Also, salvinorin A can act as a “punisher” to self-administration of cocaine or a short-acting MOPr agonist in primates (when given contingently; Whitfield et al., 2015).”
The correct sentence and citation are as follows:
“Also, salvinorin A can act as a “punisher” to self-administration of cocaine or a short-acting MOPr agonist in primates (when given contingently; Freeman et al., 2014).”
The authors apologize for the mistake. This error does not change the scientific conclusions of the review.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
FreemanK. B.NaylorJ. E.PrisinzanoT. E.WoolvertonW. L. (2014). Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl.)231, 2751–2758. 10.1007/s00213-014-3436-2
Summary
Keywords
kappa-opioid receptor, dynorphins, salvinorin A, Salvia divinorum, depression, addiction
Citation
Butelman ER and Kreek MJ (2015) Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front. Pharmacol. 6:285. doi: 10.3389/fphar.2015.00285
Received
16 November 2015
Accepted
16 November 2015
Published
30 November 2015
Volume
6 - 2015
Edited and reviewed by
George Panagis, University of Crete, Greece
Updates
Copyright
© 2015 Butelman and Kreek.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eduardo R. Butelman butelme@rockefeller.edu
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.